John Maraganore

Chief Executive Officer at Alnylam Pharmaceuticals, Inc.

John Maraganore

John Maraganore

Chief Executive Officer at Alnylam Pharmaceuticals, Inc.

Overview

Career Highlights

Alnylam Pharmaceuticals, Inc.

RelSci Relationships

4778

Number of Boards

16

Birthday

1963

Age

58

Contact Data

Trying to get in touch with John Maraganore? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!

Relationships

View Relationship Details

RelSci Relationships are individuals John Maraganore likely has professional access to. A relationship does not necessarily indicate a personal connection.

Phillip Sharp

Co-Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Michael W. Bonney

Executive Officer, Director at Adolor Corp.

Relationship likelihood: Strong

Kevin P. Starr

Co-Founder at Third Rock Ventures LLC

Relationship likelihood: Strong

Paul Schimmel

Co-Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Steven M. Paul

Former Venture Partner at Third Rock Ventures LLC

Relationship likelihood: Strong

Laurie Keating

Executive Vice President, Chief Legal Officer & Secretary at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

David Schenkein

General Partner at Google Ventures

Relationship likelihood: Strong

Rachel Meyers

Vice President of Research & RLD at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Akshay K. Vaishnaw

President-Research & Development at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Sean A. McCarthy

President, Chief Executive Officer & Chairman at CytomX Therapeutics, Inc.

Relationship likelihood: Strong

Reveal deeper insights into your organization's relationships
with RelSci Contact Aggregator.

Empower Your Business Applications with Industry-Leading
Relationship Data from the RelSci API.

Get Contact Information on the
World's Most Influential Decision Makers.

Discover the Power of Your Network with
RelSci Premium Products.

In The News

FiercePharma

March 31, 2021

Longtime Gilead captain John Martin, mastermind of lifesaving HIV, hep C drugs, has died

Business Wire

March 11, 2021

Alnylam Issues Inaugural Corporate Responsibility Summary; - New Strategic Framework Highlights Alnylam's Approach to Corporate Responsibility, Establishing the Foundation for Continuous Tracking of Initiatives and Progress -

RelSci

March 8, 2021

John Maraganore sold $4.76M worth of shares in Alnylam Pharmaceuticals, Inc. in February 2021

Nasdaq

February 11, 2021

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity

Business Wire

February 11, 2021

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity; ? Achieved Fourth Quarter and Full Year 2020 Global Net Product Revenues of $113 Million and $362 Million, Respectively -; ? Achieve

Paths to John Maraganore

Potential Connections via
Relationship Science

You

John Maraganore

Chief Executive Officer at Alnylam Pharmaceuticals, Inc.

Education

MS in Biochemistry & Molecular Biology

The University of Chicago

UCE’s Office of Investments is responsible for managing the University's investment assets, which includes overseeing the endowment to ensure that it benefits both current and future generations of the University of Chicago. They oversee the broad investment strategy and provide input to the development of the strategic and tactical investment policies of the University & UCMC endowments, pension plans and self-insurance trust assets. Their strategy combines qualitative and quantitative analysis, seeking to achieve superior investment performance on a risk-adjusted basis.

Memberships

Member

Current

CEO Action for Diversity & Inclusion

CEO Action For Diversity & Inclusion is the CEO-driven business commitment to advance diversity and inclusion within the workplace. The company is headquartered in Chicago, IL.

Career History

General Manager

Prior

Millennium Biotherapeutics, Inc.

General Manager of Millennium BioTherapeutics

2000 - 2002

Takeda Oncology Co.

Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

Director-Market & Business Development

Prior

Biogen MA, Inc.

Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA.

Boards & Committees

Lead Independent Director

2011 - Current

Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Board Advisor

2009 - Current

Proclara Biosciences, Inc.

Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA.

Director & Chief Executive Officer

Current

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. The firm's products include ONPATTRO, GIVLAARI, and OXLUMO. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Member, Board of Directors

Current

Biotechnology Innovation Organization

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Member, Research Advisory Board

Current

Beth Israel Deaconess Hospital - Needham, Inc.

Beth Israel Deaconess Hospital operates as a teaching hospital of Harvard Medical School. It offers care for cancer, cardiovascular, diabetes and spine. The company is headquartered in Needham, MA.

Member, Immunology Advisory Council

Tenure Unconfirmed

Harvard University - Harvard Medical School

Harvard Medical School (HMS) is the graduate medical school of Harvard University. It is located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts.The school was founded by John Warren on September 19, 1782, with Benjamin Waterhouse, and Aaron Dexter.

Political Donations

$625

2017

Biotechnology Industry Organization Political Action Committee

$625

2017

Biotechnology Industry Organization Political Action Committee

$625

2016

Biotechnology Industry Organization Political Action Committee

Investments

Details Hidden

Flex Pharma, Inc.

Flex Pharma, Inc. operates as a clinical-stage biotechnology company. It operates through the Consumer Operations and Drug Development segments. The Consumer Operations segment includes HOTSHOT product and consumer operations. The Drug Development segment engages in the development of innovative and proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions. The company was founded by Rod MacKinnon, Bruce Bean, Christoph Westphal, Rich Aldrich, Michelle Dipp, and Jennifer M. Cermak in February 2014 and is headquartered in Boston, MA.

Public Holdings

Restricted data only for RelSci Professional users.

Other Affiliations

John Maraganore is affiliated with Millennium Biotherapeutics, Inc., Takeda Oncology Co., Biogen MA, Inc., ZymoGenetics, Inc., Upjohn Company of Canada, Alnylam Pharmaceuticals, Inc., Third Rock Ventures LLC, The Upjohn Co., Takeda Pharmaceutical Co., Ltd., Archemix Corp., Third Rock Ventures GP LP, Biogen Idec, Inc. (North Carolina), bluebird bio, Inc., Biogen, Inc., Agios Pharmaceuticals, Inc., Proclara Biosciences, Inc., Alnylam Pharmaceuticals, Inc., CytomX Therapeutics Holdings LLC, Longwood Fund Management LLC, Tempero Pharmaceuticals, Inc., CytomX Therapeutics, Inc., bluebird bio, Inc., Taligen Therapeutics, Inc., Regulus Therapeutics, Inc., MacroGenics, Inc., Archemix Corp., Molecular Biology Resources, Inc., Biotechnology Innovation Organization, Beth Israel Deaconess Hospital - Needham, Inc., Harvard University - Harvard Medical School

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by John Maraganore. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of John Maraganore's profile does not indicate a business or promotional relationship of any kind between RelSci and John Maraganore.